The Lancet published february 18 contained an article with further findings from the ACCOMPLISH trial. The following extract summarizes some of the findings:

This trial shows that in patients with hypertension at high risk for cardiovascular events, combination treatment with benazepril plus amlodipine reduces progression of chronic kidney disease more effectively than does benazepril plus hydrochlorothiazide. This benefit was also seen when cardiovascular or all-cause mortality were assessed with progression of chronic kidney disease. Differences in blood pressure control throughout the study could not account for these findings.*

Read the abstract at theLancet.com or read more about A+ Science involvement

*From the discussion of DOI:10.1016/S0140-6736(09)62100-0

A+ Science is a Nordic Contract Research Organisation, planning and conducting clinical trials on behalf of drug and medical device developers from all over the world. We help our customers bring their products to market faster.

In addition to traditional CRO services, we offer controlled patient recruitment, mobile research units and outsourcing of research staff directly to site.